Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study - Top-Institutions - MDSpire

Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study

  • By

  • Francesca Rifaldi

  • Martina Angi

  • Giuseppe Leone

  • Marta De Ponti

  • Marta Vaiani

  • Andrea Spagnoletti

  • Alice Indini

  • Michele Del Vecchio

  • Lorenza Alessia Di Guardo

  • April 24, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Ocular Oncology
    • Medical Oncology
    • Radiation Oncology
    • Immunotherapy

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Ocular Oncology
    • Medical Oncology
    • Radiation Oncology
    • Translational Research

  • #3

    Wills Eye Hospital / Thomas Jefferson University
    Wills Eye Hospital / Thomas Jefferson University

    Philadelphia, PA

    Key Differentiators

    • Ocular Oncology
    • Radiation Oncology
    • Immunotherapy

  • #4

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Cancer Immunotherapy
    • Ocular Oncology Research
    • Radiation Oncology

Original Source(s)

Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study

  • by Francesca Rifaldi, Martina Angi, Giuseppe Leone, Marta De Ponti, Marta Vaiani, Andrea Spagnoletti, Alice Indini, Michele Del Vecchio, Lorenza Alessia Di Guardo

  • April 24, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma